Endocrine therapy is routinely recommended as first-line treatment for patients who have hormone receptor (ER and/or progesterone receptor)-positive disease without life-threatening disease or systemic symptoms requiring immediate palliation for comfort. Although higher response rates are achieved with chemotherapy, the incidence of potentially debilitating and serious toxicity is also increased, and there is no evidence that patients live longer because of receiving initial chemotherapy. Treatment could include fulvestrant alone or in combination with aromatase inhibitors or fulvestrant with CDK 4/6 inhibitors.
Learn more about the management of metastatic breast cancer.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer? - Medscape - Dec 21, 2021.